Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi has initiated a clinical study titled ‘Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA.’ The study aims to assess the safety and efficacy of iGlarLixi, a combination of insulin glargine and lixisenatide, in adults with Type 2 diabetes.
The intervention being tested is iGlarLixi, an experimental drug administered subcutaneously. It combines insulin glargine and lixisenatide, designed to improve blood sugar control in patients inadequately managed with existing treatments.
This interventional study follows a single-group assignment model without masking, focusing on evaluating the drug’s safety and efficacy. The primary purpose is to explore its potential benefits for patients with Type 2 diabetes.
The study began on January 6, 2025, with an estimated treatment duration of 24 weeks. The latest update was submitted on July 14, 2025, indicating ongoing recruitment efforts.
Sanofi’s continued investment in diabetes treatment could positively influence its stock performance and investor sentiment, especially if the study yields favorable results. This development positions Sanofi competitively within the diabetes treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.